Search

Your search keyword '"Michelson, Eric L."' showing total 203 results
Start Over "Michelson, Eric L." Language english
203 results on '"Michelson, Eric L."'

1. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy

Author

Scirica, Benjamin M., Cannon, Christopher P., Emanuelsson, Håkan, Michelson, Eric L., Harrington, Robert A., Husted, Steen, James, Stefan, Katus, Hugo, Pais, Prem, Raev, Dimitar, Spinar, Jindrich, Steg, Ph. Gabriel, Storey, Robert F., and Wallentin, Lars

Published
2011
Full Text
View/download PDF

10. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Author

Ducharme, Anique, Swedberg, Karl, Pfeffer, Marc A., Cohen-Solal, Alain, Granger, Christopher B., Maggioni, Aldo P., Michelson, Eric L., McMurray, John J.V., Olsson, Lars, Rouleau, Jean L., Young, James B., Olofsson, Bertil, Puu, Margareta, and Yusuf, Salim

Subjects
Atrial fibrillation -- Prevention, Heart failure -- Complications and side effects, Heart failure -- Care and treatment, Mortality -- Evaluation, Cardiac patients -- Care and treatment, Angiotensin -- Receptors, Angiotensin -- Physiological aspects, Angiotensin -- Research, Health
Published
2006

11. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)--added trial

Author

McMurray, John J.V., Young, James B., Dunlap, Mark E., Granger, Christopher B., Hainer, James, Michelson, Eric L., Earle, Steven, Olofsson, Bertil, Ostergren, Jan, Yusuf, Salim, Swedberg, Karl, and Pfeffer, Marc A.

Subjects
Angiotensin converting enzyme -- Research, Angiotensin converting enzyme -- Physiological aspects, Heart failure -- Research, Heart failure -- Care and treatment, Mortality -- Evaluation, Candesartan -- Research, Candesartan -- Physiological aspects, Health
Published
2006

12. Feasibility of treating prehypertension with an angiotensin-receptor blocker

Author

Julius, Stevo, Nesbitt, Shawna, Egan, Brent M., Weber, Michael A., Oparil, Suzanne, Schork, Anthony M., Michelson, Eric L., Kaciroti, Niko, Black, Henry R., Grimm, Richard H., and Messerli, Franz H.

Subjects
Hypertension -- Drug therapy, Candesartan -- Dosage and administration, Candesartan -- Research
Abstract

A test was conducted to investigate whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension. Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension indicating that pharmacological treatment of hypertension is feasible.

Published
2006

13. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

Author

Granger, Bradi B., Swedberg, Karl, Ekman, Inger, Granger, Christopher B., Olofsson, Bertil, McMurray, John J.V., Yusuf, Salim, Michelson, Eric L., and Pfeffer, Marc A.

Subjects
Heart failure -- Risk factors, Heart failure -- Complications and side effects, Heart failure -- Care and treatment, Heart failure -- Analysis, Heart failure -- Patient outcomes
Published
2005

14. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

Author

Demers, Catherine, McMurray, John J.V., Swedberg, Karl, Pfeffer, Marc A., Granger, Christopher B., Olofsson, Bertil, McKelvie, Robert S., Ostergren, Jan, Michelson, Eric L., Johansson, Peter A., Duolao Wang, and Yusuf, Salim

Subjects
Candesartan -- Dosage and administration, Candesartan -- Complications and side effects, Heart attack -- Drug therapy, Cardiac patients -- Medical examination
Abstract

A program is carried out with heart patients to study the effect of the angiotensin receptor blocker candesartan on myocardial infarction (MI) and other coronary disorders. Findings prove that the danger of the combined outcome of cardiovascular death or nonfatal MI markedly decreases with candesartan.

Published
2005

17. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

Author

Christian, Jennifer B., Finkle, John K., Ky, Bonnie, Douglas, Pamela S., Gutstein, David E., Hockings, Paul D., Lainee, Pierre, Lenihan, Daniel J., Mason, Jay W., Sager, Philip T., Todaro, Thomas G., Hicks, Karen A., Kane, Robert C., Ko, Hon-Sum, Lindenfeld, JoAnn, Michelson, Eric L., Milligan, James, Munley, Jiefen Y., Raichlen, Joel S., Shahlaee, Amir, Strnadova, Colette, Ye, Brenda, and Turner, Rick J.

Published
2012
Full Text
View/download PDF

20. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme

Author

Chang, Su Min, Granger, Christopher B., Johansson, Peter A., Kosolcharoen, Peter, McMurray, John J.V., Michelson, Eric L., Murray, David R., Olofsson, Bertil, Pfeffer, Marc A., Solomon, Scott D., Swedberg, Karl, Yusuf, Salim, and Dunlap, Mark E.

Published
2010
Full Text
View/download PDF

34. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

Author

Granger, Christopher B, Ertl, Georg, Kuch, Jerzy, Maggioni, Aldo P, McMurray, John, Rouleau, Jean-Lucien, Stevenson, Lynn Warner, Swedberg, Karl, Young, James, Yusuf, Salim, Califf, Robert M, Bart, Bradley A, Held, Peter, Michelson, Eric L, Sellers, Mary Ann, Ohlin, Gunilla, Sparapani, Rodney, and Pfeffer, Marc A

Published
2000

39. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program

Author

Castagno, Davide, Skali, Hicham, Takeuchi, Madoka, Swedberg, Karl, Yusuf, Salim, Granger, Christopher B., Michelson, Eric L., Pfeffer, Marc A., McMurray, John J.V., and Solomon, Scott D.

Subjects
heart rate, heart failure, atrial fibrillation, prognosis, ejection fraction
Abstract

ObjectivesThe aim of this study was to explore the relationship between baseline resting heart rate and outcomes in patients with chronic heart failure (HF) according to baseline left ventricular ejection fraction (LVEF) and cardiac rhythm.BackgroundElevated resting heart rate is associated with worse outcomes in patients with HF and reduced LVEF. Whether this association is also found in patients with HF and preserved LVEF is uncertain, as is the predictive value of heart rate in patients in atrial fibrillation (AF).MethodsPatients enrolled in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program were divided into groups by tertiles of baseline heart rate. Cox proportional hazard models were used to investigate the association between heart rate and pre-specified outcomes in the overall population as well as in subgroups defined according to LVEF (≤40% vs. >40%) and presence (or absence) of AF at baseline.ResultsAfter adjusting for predictors of poor prognosis, patients in the highest heart rate tertile had worse outcomes when compared with those in the lowest heart rate group (e.g., for the composite of cardiovascular death or HF hospital stay hazard ratio: 1.23, 95% confidence interval: 1.11 to 1.36, p < 0.001). The relationship between heart rate and outcomes was similar across LVEF categories and was not influenced by beta-blocker use (p value for interaction >0.10 for both endpoints). However, amongst patients in AF at baseline, heart rate had no predictive value (p value for interaction

Published
2012

40. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy

Author

Scirica, Benjamin M, Cannon, Christopher P, Emanuelsson, Håkan, Michelson, Eric L, Harrington, Robert A, Husted, Steen, James, Stefan, Katus, Hugo, Pais, Prem, Raev, Dimitar, Spinar, Jindrich, Steg, Ph Gabriel, Storey, Robert F, and Wallentin, Lars

Subjects
Male, Adenosine, Ticlopidine, Time Factors, Incidence, Middle Aged, Electrocardiography, Treatment Outcome, Bradycardia, Humans, Female, cardiovascular diseases, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Aged
Abstract

The aim of this study was to determine whether ticagrelor increased the risk of ventricular pauses compared with clopidogrel and whether these pauses were associated with any clinical bradycardic events in patients presenting with acute coronary syndromes.

Published
2011

41. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

Author

Bui, An H., Cannon, Christopher P., Steg, Philippe Gabriel, Storey, Robert F., Husted, Steen, Guo, Jianping, Im, KyungAh, James, Stefan K., Michelson, Eric L., Himmelmann, Anders, Held, Claes, Varenhorst, Christoph, Wallentin, Lars, and Scirica, Benjamin M.

Subjects
PLATELET aggregation inhibitors, ADENOSINES, CARDIAC arrest, COMPARATIVE studies, CAUSES of death, ELECTROCARDIOGRAPHY, RESEARCH methodology, MEDICAL cooperation, PEPTIDE hormones, PEPTIDES, RESEARCH, RISK assessment, TICLOPIDINE, TIME, EVALUATION research, VENTRICULAR tachycardia, RANDOMIZED controlled trials, TREATMENT effectiveness, DISEASE incidence, ACUTE coronary syndrome, DISEASE complications, DIAGNOSIS, THERAPEUTICS
Abstract

Background: Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and a marker of increased risk of arrhythmogenic death. However, the prognostic significance of NSVT when evaluated with other contemporary risk markers and at later time points after ACS remains uncertain.Methods and Results: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, continuous ECGs were performed during the first 7 days after ACS (n=2866) and repeated for another 7 days at day 30 (n=1991). Median follow-up was 1 year. There was a time-varying interaction between NSVT and cardiovascular death such that NSVT was significantly associated with increased risk within the first 30 days after randomization (22/999 [2.2%] versus 16/1825 [0.9%]; adjusted hazard ratio, 2.84; 95% confidence interval, 1.39-5.79; P=0.004) but not after 30 days (28/929 [3.0%] versus 42/1734 [2.4%]; P=0.71). Detection of NSVT during the convalescent phase (n=428/1991; 21.5%) was also associated with an increased risk of cardiovascular death, and was most marked within the first 2 months after detection (1.9% versus 0.3%; adjusted hazard ratio, 5.48; 95% confidence interval, 1.07-28.20; P=0.01), and then decreasing over time such that the relationship was no longer significant by ≈5 months after ACS.Conclusions: NSVT occurred frequently during the acute and convalescent phases of ACS. The risk of cardiovascular death associated with NSVT was the greatest during the first 30 days after presentation; however, patients with NSVT detected during the convalescent phase were also at a significantly increased risk of cardiovascular death that persisted for an additional several months after the index event.Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT00391872. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme.

Author

Su Min Chang, Granger, Christopher B., Johansson, Peter A., Kosolcharoen, Peter, McMurray, John J. V., Michelson, Eric L., Murray, David R., Olofsson, Bertil, Pfeffer, Marc A., Solomon, Scott D., Swedberg, Karl, Yusuf, Salim, and Dunlap, Mark E.

Subjects
CHEMICAL inhibitors, ANGIOTENSINS, ASPIRIN, CANDESARTAN, HEART failure patients, DRUG efficacy
Abstract

Aims: It is unknown whether there is an interaction between aspirin and angiotensin receptor blockers on outcomes in patients with heart failure (HF). [ABSTRACT FROM PUBLISHER]

Published
2010
Full Text
View/download PDF

50. The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure.

Author

Gerstein, Hertzel C., Swedberg, Karl, Carlsson, Jonas, McMurray, John J. V., Michelson, Eric L., Olofsson, Bertil, Pfeffer, Marc A., and Yusuf, Salim

Subjects
DISEASE risk factors, HEMOGLOBINS, PROGRESSIVE patient care, HEART failure, MORTALITY, CARDIOVASCULAR diseases, HOSPITAL care, CHRONIC diseases, RESEARCH
Abstract

The article presents a study which examines the role of hemoglobin A1c levels as progressive risk factors for cardiovascular (CV) events in patients with symptomatic chronic heart failure (HF). The study focused on participants of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. An analysis of the incidence of cardiovascular death, hospitalization for heart failure and total mortality in patients with chronic heart failure was also conducted.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results